Filter posts

Pfizer CEO: How the Biopharmaceutical Industry Creates Value (And Jobs) for the U.S. Economy

In a recent piece for Forbes, Pfizer’s Chairman and CEO Ian Read highlights the significant …

As Out-of-Pocket Costs Rise, Insurers Spend Big on Administrative Costs

It seems every week the insurance industry is busy pointing the finger at biopharmaceutical innovators …

Greenwood: America Leads in Biopharmaceutical Innovation. Let’s Keep It That Way.

Writing last week for Morning Consult, BIO President and CEO Jim Greenwood proposed several policy …

Insurers Should Prevent Pharmacy Counter Sticker Shock, Not Encourage It

Sticker shock at the pharmacy counter is becoming increasingly more common for patients across the …

Insurers and PBMs Limit Access to Safer Opioid Alternatives

Opioid abuse and addiction in America continues to ravish communities, families, and individuals across the …

Debunking a Common Myth on Out-of-Pocket Costs

The facts continue to show that, when it comes to prescription drug costs, the country …

Four Questions for the Energy and Commerce Hearing on 340B

Later this morning, the House Energy and Commerce Committee will hold a hearing to examine …

FDA Protects Patients While Promoting Innovation

Today, 83 percent of children with cancer survive, compared to just 58 percent in the …

I-MAK’s Distorted View of the U.S. Patent System

In an opinion piece published at CNBC.com, Tahir Amin — co-founder of I-MAK — blames …

Co-Pay Accumulator Programs Are a Bad Deal for Patients

As we see time and time again, health insurance providers and pharmacy benefit managers (PBMs) …